P&T committees--black boxes versus AMCP format, and what is the true cost and value of pimecrolimus.
Curtiss
Frederic R
FR
D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects; D003876:Dermatitis, Atopic / Q000188:drug therapy; D017723:Drug Utilization Review / Q000191:economics; D019317:Evidence-Based Medicine / Q000379:methods; D005569:Formularies as Topic / Q000592:standards; D006356:Heartburn / Q000188:drug therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000627:therapeutic use; D006967:Hypersensitivity / Q000188:drug therapy; D007356:Insurance, Pharmaceutical Services / Q000191:economics / Q000706:statistics & numerical data; D004366:Nonprescription Drugs / Q000191:economics / Q000627:therapeutic use; D011367:Professional Staff Committees; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use
D016861:Cyclooxygenase Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D004366:Nonprescription Drugs; C117268:pimecrolimus; D016559:Tacrolimus